# Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

> **NCT00294372** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** BILR 355 BS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00294372
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 36 (—)
- **Last updated:** 2013-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00294372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00294372, "Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00294372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*